An EC 3.4.15.* (peptidyl-dipeptidase) inhibitor that interferes with the action of peptidyl-dipeptidase A (EC 3.4.15.1).
| Member | Definition | Class |
|---|
| alacepril | | Alacepril |
| benazepril | A benzazepine that is benazeprilat in which the carboxy group of the 2-amino-4-phenylbutanoic acid moiety has been converted to the corresponding ethyl ester. It is used (generally as its hydrochloride salt) as a prodrug for the angiotensin-converting enzyme inhibitor benazeprilat in the treatment of hypertension and heart failure. | benazepril |
| benazeprilat | A benzazepine that is 1,3,4,5-tetrahydro-2H-1-benzazepin-2-one in which the hydrogen attached to the nitrogen is replaced by a carboxy methyl group and in which the 3-pro-S hydrogen is replaced by the amino group of (2S)-2-amino-4-phenylbutanoic acid. An angiotensin-converting enzyme inhibitor, it is used as its monoester prodrug benazepril in the treatment of hypertension and heart failure. | benazeprilat |
| captopril | A L-proline derivative in which L-proline is substituted on nitrogen with a (2S)-2-methyl-3-sulfanylpropanoyl group. It is used as an anti-hypertensive ACE inhibitor drug. | captopril |
| ci 906 | A hydrochloride resulting from the reaction of equimolar amounts of quinapril and hydrogen chloride. A prodrug for quinaprilat hydrochloride (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) for the treatment of hypertension and congestive heart failure. | quinapril hydrochloride |
| cilazapril, anhydrous | A pyridazinodiazepine resulting from the formal condensation of the carboxy group of cilazaprilat with ethanol. It is a drug used in the treatment of hypertension and heart failure. | cilazapril |
| corilagin | An ellagitannin with a hexahydroxydiphenoyl group bridging over the 3-O and 6-O of the glucose core. | corilagin |
| enalapril | A dicarboxylic acid monoester that is ethyl 4-phenylbutanoate in which a hydrogen alpha to the carboxy group is substituted by the amino group of L-alanyl-L-proline (S-configuration). | enalapril |
| enalapril maleate | The maleic acid salt of enalapril. It contains one molecule of maleic acid for each molecule of enalapril. Following oral administration, the ethyl ester group of enalapril is hydrolysed to afford the corresponding carboxylic acid, enalaprilat, an angiotensin-converting enzyme (ACE) inhibitor. Enalapril is thus a prodrug for enalaprilat (which, unlike enalapril, is not absorbed by mouth), and its maleate is used in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. | enalapril maleate |
| enalaprilat anhydrous | Enalapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid. Enalaprilat is an angiotensin-converting enzyme (ACE) inhibitor and is used (often in the form of its prodrug, enalapril) in the treatment of hypertension and heart failure, for reduction of proteinuria and renal disease in patients with nephropathies, and for the prevention of stroke, myocardial infarction, and cardiac death in high-risk patients. Unlike enalapril, enalaprilat is not absorbed by mouth but is given by intravenous injection, usually as the dihydrate. | enalaprilat (anhydrous) |
| fosinoprilat | A phosphinic acid-containing N-acyl derivative of (4S)-cyclohexyl-L-proline. An inhibitor of angiotensin converting enzyme (ACE), it is used as the phosphinate ester pro-drug fosinopril for treatment of hypertension and chronic heart failure. | fosinoprilat |
| imidapril | A member of the class of imidazolidines that is (4S)-1-methyl-2-oxoimidazolidine-4-carboxylic acid in which the hydrogen of the imidazolidine nitrogen has been substituted by (1S)-1-{[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino}ethyl group. It is the prodrug for imidaprilat, an ACE inhibitor used for the treatment of chronic heart failure. | imidapril |
| imidaprilat | A member of the class of imidazolidines that is imidapril in which the ethyl ester group has been hydrolysed to the corresponding acid group. It is the active metabolite of imidapril used to treat hypertension. | imidaprilat |
| lisinopril | | lisinopril |
| lotensin | A hydrochloride salt resulting from the reaction of benazepril with 1 mol eq. of hydrogen chloride. It is used as a prodrug for angiotensin-converting enzyme inhibitor benazeprilat in the treatment of hypertension and heart failure. | benazepril hydrochloride |
| nicotianamine | The (S,S,S)-stereoisomer of nicotianamine. | (S,S,S)-nicotianamine trizwitterion; (S,S,S)-nicotianamine |
| perindopril | An alpha-amino acid ester that is the ethyl ester of N-{(2S)-1-[(2S,3aS,7aS)-2-carboxyoctahydro-1H-indol-1-yl]-1-oxopropan-2-yl}-L-norvaline | perindopril |
| perindopril erbumine | | perindopril erbumine |
| perindoprilat | A dipeptide obtained by formal condensation of one of the carboxy groups of N-[(1S)-1-carboxyethyl]-L-norvaline with the amino group of (2S,3aS,7aS)-octahydroindole-2-carboxylic acid. The major active metabolite of perindopril. | perindoprilat |
| quinapril | A member of the class of isoquinolines that is (3S)-2-L-alanyl-1,2,3,4-tetrahydroisoquinoline-3-carboxylic acid in which the alpha-amino group of the alanyl residue has been substituted by a 1-ethoxycarbonyl-4-phenylbutan-2-yl group (the all-S isomer). A prodrug for quinaprilat (by hydrolysis of the ethyl ester to the corresponding carboxylic acid), it is used as an angiotensin-converting enzyme inhibitor (ACE inhibitor) used (generally as the hydrochloride salt) for the treatment of hypertension and congestive heart failure. | quinapril |
| quinaprilat | A dicarboxylic acid resulting from the hydrolysis of the ethyl ester group of quinapril to give the corresponding dicarboxylic acid. The active angiotensin-converting enzyme inhibitor (ACE inhibitor) of the prodrug quinapril. | quinaprilat |
| ramipril | A dipeptide that is the prodrug for ramiprilat, the active metabolite obtained by hydrolysis of the ethyl ester group. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure. | ramipril |
| ramiprilat | A dipeptide that is the active metabolite of ramipril. An angiotensin-converting enzyme (ACE) inhibitor, used to treat high blood pressure and congestive heart failure. | ramiprilat |
| spirapril | | spirapril |
| spiraprilat | An azaspiro compound that is spirapril in which the ethyl ester group has been hydrolysed to the corresponding carboxylic acid group. It is the active metabolite of the angiotensin-converting enzyme (ACE) inhibitor spirapril. | spiraprilat |
| telmisartan | A member of the class of benzimidazoles used widely in the treatment of hypertension. | telmisartan |
| trandolapril | A heterobicylic compound that is (2S,3aR,7aS)-1-[(2S)-2-aminopropanoyl]octahydro-1H-indole-2-carboxylic acid in which the hydrogen of the amino group is substituted by a (2R)-1-ethoxy-1-oxo-4-phenylbutan-2-yl group. It is a angiotensin-converting enzyme inhibitor and a prodrug used for the treatment of hypertension. | trandolapril |
| trandolaprilat | A heterobicyclic compound that is trandolapril in which the ethyl ester group has been hydrolysed to the corresponding acid group. It is the active metabolite of the prodrug trandolapril. | trandolaprilat |
| zofenopril | A proline derivative that is 4-(phenylsulfanyl)-L-proline in which the amine proton is replaced by a (2S)-3-(benzoylsulfanyl)-2-methylpropanoyl group. A prodrug for zofenoprilat. | zofenopril |
| zofenoprilate | A proline derivative that is 4-(phenylsulfanyl)-L-proline in which the amine proton is replaced by a (2S)-2-methyl-3-sulfanylpropanoyl group. The active metabolite of zofenopril. | zofenoprilat |
| Protein | Taxonomy | Measurement | Average (mM) | Bioassay(s) | Drugs |
|---|
| 15-lipoxygenase, partial | Homo sapiens (human) | Potency | 25.1189 | 1 | 1 |
| activating transcription factor 6 | Homo sapiens (human) | Potency | 21.7348 | 2 | 3 |
| aldehyde dehydrogenase 1 family, member A1 | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| AR protein | Homo sapiens (human) | Potency | 19.1955 | 9 | 15 |
| aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 14.9099 | 2 | 3 |
| arylsulfatase A | Homo sapiens (human) | Potency | 0.6746 | 1 | 1 |
| ATP-dependent phosphofructokinase | Trypanosoma brucei brucei TREU927 | Potency | 30.1313 | 1 | 1 |
| bromodomain adjacent to zinc finger domain 2B | Homo sapiens (human) | Potency | 89.1251 | 1 | 1 |
| caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 33.4915 | 1 | 1 |
| caspase-3 | Homo sapiens (human) | Potency | 33.4915 | 1 | 1 |
| Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 12.6700 | 2 | 3 |
| Chain A, 2-oxoglutarate Oxygenase | Homo sapiens (human) | Potency | 15.8531 | 1 | 3 |
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 4.4668 | 1 | 1 |
| Chain A, HADH2 protein | Homo sapiens (human) | Potency | 35.7168 | 2 | 2 |
| Chain A, JmjC domain-containing histone demethylation protein 3A | Homo sapiens (human) | Potency | 50.1187 | 1 | 1 |
| Chain A, MAJOR APURINIC/APYRIMIDINIC ENDONUCLEASE | Homo sapiens (human) | Potency | 0.0631 | 1 | 1 |
| Chain B, HADH2 protein | Homo sapiens (human) | Potency | 35.7168 | 2 | 2 |
| chromobox protein homolog 1 | Homo sapiens (human) | Potency | 89.7164 | 1 | 2 |
| cytochrome P450 2C9, partial | Homo sapiens (human) | Potency | 10.4604 | 1 | 4 |
| cytochrome P450 2D6 | Homo sapiens (human) | Potency | 36.7866 | 1 | 2 |
| cytochrome P450 3A4 isoform 1 | Homo sapiens (human) | Potency | 15.8489 | 2 | 2 |
| cytochrome P450 family 3 subfamily A polypeptide 4 | Homo sapiens (human) | Potency | 14.7250 | 2 | 8 |
| cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 14.9601 | 1 | 1 |
| Disintegrin and metalloproteinase domain-containing protein 17 | Homo sapiens (human) | Potency | 10.0000 | 1 | 1 |
| DNA polymerase iota isoform a (long) | Homo sapiens (human) | Potency | 71.2438 | 1 | 3 |
| endonuclease IV | Escherichia coli | Potency | 0.0002 | 1 | 1 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 18.4001 | 6 | 13 |
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 18.8336 | 1 | 1 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 19.7418 | 4 | 9 |
| euchromatic histone-lysine N-methyltransferase 2 | Homo sapiens (human) | Potency | 14.7893 | 1 | 5 |
| EWS/FLI fusion protein | Homo sapiens (human) | Potency | 28.5159 | 4 | 8 |
| eyes absent homolog 2 isoform a | Homo sapiens (human) | Potency | 28.1838 | 1 | 1 |
| farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 20.7222 | 3 | 6 |
| flap endonuclease 1 | Homo sapiens (human) | Potency | 0.1683 | 1 | 1 |
| Fumarate hydratase | Homo sapiens (human) | Potency | 37.2212 | 1 | 1 |
| G | Vesicular stomatitis virus | Potency | 10.4604 | 1 | 4 |
| GABA theta subunit | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1 | 1 |
| GALC protein | Homo sapiens (human) | Potency | 0.7079 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-1 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-2 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-3 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-4 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-5 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit alpha-6 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-1 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-2 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit beta-3 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit delta | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit epsilon | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-1 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-2 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit gamma-3 | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1 | 1 |
| Gamma-aminobutyric acid receptor subunit pi | Rattus norvegicus (Norway rat) | Potency | 15.8489 | 1 | 1 |
| geminin | Homo sapiens (human) | Potency | 1.2108 | 2 | 4 |
| GLI family zinc finger 3 | Homo sapiens (human) | Potency | 16.3252 | 3 | 6 |
| glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 12.1622 | 2 | 2 |
| Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 18.8336 | 1 | 1 |
| Guanine nucleotide-binding protein G | Homo sapiens (human) | Potency | 3.1623 | 1 | 1 |
| heat shock protein beta-1 | Homo sapiens (human) | Potency | 31.6680 | 2 | 4 |
| histone acetyltransferase KAT2A isoform 1 | Homo sapiens (human) | Potency | 39.8107 | 1 | 1 |
| Histone H2A.x | Cricetulus griseus (Chinese hamster) | Potency | 61.9315 | 2 | 2 |
| histone-lysine N-methyltransferase 2A isoform 2 precursor | Homo sapiens (human) | Potency | 44.6684 | 1 | 1 |
| HLA class I histocompatibility antigen, B alpha chain | Homo sapiens (human) | Potency | 10.4604 | 1 | 4 |
| hypoxia-inducible factor 1 alpha subunit | Homo sapiens (human) | Potency | 22.9254 | 2 | 2 |
| IDH1 | Homo sapiens (human) | Potency | 23.3117 | 1 | 3 |
| Inositol hexakisphosphate kinase 1 | Homo sapiens (human) | Potency | 10.4604 | 1 | 8 |
| Interferon beta | Homo sapiens (human) | Potency | 13.0824 | 2 | 5 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 3.9437 | 1 | 4 |
| Luciferase | Photinus pyralis (common eastern firefly) | Potency | 12.1121 | 3 | 3 |
| M-phase phosphoprotein 8 | Homo sapiens (human) | Potency | 1.0000 | 1 | 1 |
| Microtubule-associated protein tau | Homo sapiens (human) | Potency | 22.6020 | 2 | 4 |
| mitogen-activated protein kinase 1 | Homo sapiens (human) | Potency | 15.8489 | 1 | 1 |
| neuropeptide S receptor isoform A | Homo sapiens (human) | Potency | 1.2589 | 1 | 1 |
| nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 36.3411 | 2 | 4 |
| nuclear factor erythroid 2-related factor 2 isoform 2 | Homo sapiens (human) | Potency | 26.1011 | 1 | 2 |
| nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 30.1065 | 1 | 1 |
| nuclear receptor subfamily 1, group I, member 2 | Rattus norvegicus (Norway rat) | Potency | 22.3872 | 1 | 1 |
| nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 21.1643 | 2 | 8 |
| parathyroid hormone/parathyroid hormone-related peptide receptor precursor | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| peripheral myelin protein 22 | Rattus norvegicus (Norway rat) | Potency | 14.3549 | 1 | 2 |
| peripheral myelin protein 22 isoform 1 | Homo sapiens (human) | Potency | 84.9214 | 1 | 1 |
| peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 11.9530 | 3 | 5 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 29.3733 | 3 | 4 |
| phosphopantetheinyl transferase | Bacillus subtilis | Potency | 44.8455 | 1 | 3 |
| polyprotein | Zika virus | Potency | 37.2212 | 1 | 1 |
| potassium voltage-gated channel subfamily H member 2 isoform d | Homo sapiens (human) | Potency | 35.4813 | 1 | 1 |
| pregnane X nuclear receptor | Homo sapiens (human) | Potency | 22.4225 | 2 | 6 |
| progesterone receptor | Homo sapiens (human) | Potency | 34.6211 | 1 | 1 |
| RAR-related orphan receptor gamma | Mus musculus (house mouse) | Potency | 16.3956 | 2 | 4 |
| retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 26.0176 | 3 | 10 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 23.9145 | 1 | 1 |
| SMAD family member 2 | Homo sapiens (human) | Potency | 19.2094 | 2 | 4 |
| SMAD family member 3 | Homo sapiens (human) | Potency | 19.2094 | 2 | 4 |
| survival motor neuron protein isoform d | Homo sapiens (human) | Potency | 2.2387 | 1 | 1 |
| TAR DNA-binding protein 43 | Homo sapiens (human) | Potency | 14.2500 | 1 | 2 |
| TDP1 protein | Homo sapiens (human) | Potency | 19.1229 | 2 | 9 |
| thioredoxin glutathione reductase | Schistosoma mansoni | Potency | 11.2202 | 1 | 1 |
| thioredoxin reductase | Rattus norvegicus (Norway rat) | Potency | 79.4328 | 1 | 1 |
| Thrombopoietin | Homo sapiens (human) | Potency | 12.5893 | 2 | 2 |
| thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 21.1240 | 2 | 6 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 34.1572 | 4 | 5 |
| transient receptor potential cation channel subfamily V member 1 | Homo sapiens (human) | Potency | 5.0119 | 1 | 1 |
| ubiquitin carboxyl-terminal hydrolase 2 isoform a | Homo sapiens (human) | Potency | 10.0000 | 1 | 1 |
| USP1 protein, partial | Homo sapiens (human) | Potency | 44.9647 | 1 | 2 |
| v-jun sarcoma virus 17 oncogene homolog (avian) | Homo sapiens (human) | Potency | 26.8325 | 2 | 2 |
| vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 23.7434 | 2 | 4 |
| vitamin D3 receptor isoform VDRA | Homo sapiens (human) | Potency | 28.1838 | 1 | 1 |
| Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 18.8336 | 1 | 1 |